Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.
Ajinomoto BioPharma Services
Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, we provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on. Ajinomoto Bio-Pharma Services is establishing itself as a premier, US-based provider for high-containment bioconjugate manufacturing, as well as fill and finish services for both Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC).
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
Cerbios- Pharma SA
Cerbios has the experience and capabilities to move your ADC project forward. We support you from early stage bioconjugation POC studies up to cGMP manufacturing for both cytotoxic and non-cytotoxic ADCs. Furthermore we provide you with development and manufacturing services for highly potent cytotoxic payloads.
Full life cycle services (including experienced consultancy, full CMC support, registration/validation material and commercial production) are granted for each project.
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.
Iksuda Therapeutics (formally Glythera) is a pre-clinical stage company developing ADCs for difficult to treat solid tumours. Our ADCs are centered around our proprietary PermaLInk® conjugation platform which provides conjugation stability by design.
Through PermaLink, we aim to develop more effective ADCs by leveraging the broad tumour activity associated with ultra-potent DNA damaging payloads, combined with clinically relevant targets.
Through our collaborations and partnerships, we are building a pipeline of superior ADCs with the goal of improving the lives of patients living with cancer.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We perform ADC sample preparation, small scale development services, customized facility design, and superior scale up of early stage processes for late stage and commercial supply. Backed by a strong reputation for industry leading analytical capabilities and quality control, Lonza can also aide in driving quick development and improving marketability of the industry’s high potential future therapies Contact email@example.com or visit
NBE-Therapeutics is a Swiss Biotechnology company developing antibody-based therapeutics. It is the main focus of NBE-Therapeutics to develop antibody drug conjugates (ADCs) for targeted cancer therapy. For this NBE-Therapeutics has developed proprietary therapeutic antibody discovery and antibody-drug conjugation technologies allowing the development of superior, “next-generation” ADCs.
NJ Bio is a quality CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors. Main service areas include multistep organic synthesis, medicinal chemistry, bioconjugation, antibody-drug conjugates, and flow chemistry. The company is headquartered in the New Jersey Bioscience Center in North Brunswick, NJ, with additional chemistry facilities in Bristol, PA, and a satellite office in Cambridge, MA. NJ Bio is affiliated with Amar Chemistry in Mumbai, India, for continuous flow and high-pressure chemistry services as well as chemical process R&D and scale-up under a Blended FTE Services model. Contact firstname.lastname@example.org or visit our website
Novasep provides unique services for the development and cGMP manufacture of antibody-drug conjugates including the payload, the linker and the monoclonal antibody. With a recent €10M investment in a fully integrated ADC facility, Novasep has reinforced its current ADC offering with full bio-conjugation services to meet increasing market demand.
SafeBridge Consultants, Inc. is the premier resource for high-level safety, health and environmental support to the pharmaceutical and biotechnology industry. Comprised of industry leaders in toxicology, analytical chemistry and industrial hygiene. SafeBridge has developed the “brand name” in the pharmaceutical industry as a leader in the field of advanced worker protection programs for potent drug handling and risk assessment for product protection. SafeBridge has locations in Mountain View, California, New York City and London, England.
SCIEX offers an innovative set of LC, MS, CE, software, and compliance and validation solutions to meet the demands of modern therapeutic discovery and development. From accurate DAR measurement and comprehensive characterization to streamlined biotransformation solution to integrated Qual/Quant and low-level quantitation of antibody drug conjugates (ADC), SCIEX provides innovative solutions to simplify your analyses and accelerate your ADC program.
Avipep Therapeutics is a pre-clinical stage biotech company that develops next-generation ADCs based upon the company's proprietary Avibody™ platform.
Avibodies™ are small, stable, high avidity antibody-derivatives that have superior biodistribution and tumor penetration compared with traditional intact IgGs. Clinical trial results in cancer patients have shown that Avibodies can rapidly and efficiently penetrate tumors. They durably persist within the tumor for weeks while clearing from the systemic circulation within hours.
Avibodies can deliver highly potent payloads with far less toxicity and can be reformatted from existing intact antibodies. Please contact us to discuss collaboration or license.
CARBOGEN AMCIS combines world-class chemistry skills to provide seamless drug development and commercialization services for pharmaceutical and biotechnology companies. Through our customized offering we provide an array of integrated process research and manufacturing services to support the fast supply of complex Antibody Drug Conjugates (ADCs). Our infrastructure is fully cGMP compliant and includes a clean room dedicated to ADCs in Switzerland and a formulation site with lyophilization capabilities in France.
Minakem is a technology driven outsourcing partner dedicated to developing and manufacturing fine chemicals, advanced intermediates, APIs and HPAPIs including ADC toxins. A dedicated site having more than 40 years’ experience in high potent compounds, with state-of-the-art containment systems and capability to handle broad range of chemistry from grams to kilos scale, including preparative-HPLC, makes Minakem a partner of choice in HPAPI and ADC toxins development and supply across the full product life cycle.
ReachBio provides primary cell biology contract research services to the drug development and life science research community. With a special focus on hematopoietic (blood and bone marrow) primary cell systems, our platform is broad and includes predictive and investigative toxicology, immunology, efficacy testing, cell bank development, biomarker selection, flow cytometry/cell sorting, and assay development and. ReachBio has developed two distinct assay platforms to assess cytotoxicity caused by ADCs.
European leader in analytical sciences – Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products. The company holds a unique position on the market thanks to having all its laboratories on one site, 170 highly qualified professionals and more than 35 years’ expertise at the forefront of analytical sciences.